Get started

GUFICBIO

Gufic Biosciences Limited - Breakout Setup, Move is ON...#GUFICBIO trading above Resistance of 369 Next Resistance is at 496 Support is at 242 Here is previous chart: Chart is self explanatory. Levels of breakout, possible up-moves (where stock may find resistances) and support (close below which, setup will be invalidated) are clearly defined. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
NSE:GUFICBIOLong
by MandeepSinghKohli
1
GUFICBIO is Set to rally! Time to go Long!Hey Family, there is a one more stock Which is showing a great opportunity. Key Points:- * Formation of Symmetrical Triangle Pattern in Daily TF. * From June 2024 to Aug 2024 its in range. * After June 2024 Breakout goes to sideways in July Starting & Now it's breaking the sideways level again in Aug 2024. * It's Break resistance Zone and trying to sustain above Resistance Zone with good volume, Good Closing is required for good move. * Already tested resistance many times. * Volume Accumulation (Volume is Building). What is your view please comment it down and also boost the idea this help to motivate us. We are Certified. All views shared on this channel are my personal opinion and is shared for educational purpose and should not be considered advise of any nature.
NSE:GUFICBIOLong
by ChartSight
3
Short Term Trading Opportunity in Gufic bio for 10% UpsideHi, NSE:GUFICBIO has given a Bullish Flag Breakout on Daily charts with very good volume. MACD is also on the bullish side on Daily and Monthly time frames. RSI is also on the bullish side on daily, weekly and monthly time frames. In the current market scenario, I am expecting that the bullish momentum will continue. Complete price projection like entry, stop loss and targets mentioned on the charts for educational purpose. Don't Forget to Follow me to get all the updates. Please share your feedback or any queries on the study. Disclaimer: Please consult your financial advisor before making any investment decision.
NSE:GUFICBIOLong
by raigvivek
GUFICBIO - Ichimoku BreakoutStock Name - Gufic Biosciences Limited Ichimoku Cloud Setup : 1). Today's close is above the Conversion Line 2). Future Kumo is Turning Bullish 3). Chikou span is slanting upwards All these parameters are showing bullishness at Current Market Price and more bullishness AFTER crossing 308 #This is not Buy and Sell recommendation to any one. This is for education purpose and a helping hand to learn trading in Market. #CloudTrading #IchimokuCloud #IchimokuFollowers #Ichimokuexpert I hope you all like my analysis. Please do share your thoughts into comment section. Please give a like, share & subscribe for daily analysis.
NSE:GUFICBIOLong
by nikunjbhadja
YR 2022 Idea #150: Long on GUFICBIO This is a public swing trade idea and is only for Learning and observational purpose. Please understand your risk and take full responsibility of your actions. I might trail my stoploss after I get an entry but even if my original Stoploss hits, i exit the trade with pre-planned loss (risk). At target, I book usually 75% positions and trail stoploss for rest. Our objective to help anyone who wants to learn technical analysis using charts by demonstrating my real trade entries. You can post your queries in comment section here and we will try to answer them asap.
NSE:GUFICBIOLong
by onerighttrade
Gufic breakout, pullback & bounce back 1. Buy or Sell at your own risk 2. Don't risk more than 1%-2% of your capital as stop loss 3. Position Size formula:- Stop Loss Amount/(Buy Price-Initial Stop Loss Price) 4. Sell on initial stop loss hit or daily RSI closing below 40 5. Some other ways to sell stocks can be a. 25% or 50% up in three weeks or less b. Weekly tailing tops with high volume c. Exhaustion gaps d. Heavy daily volume without further upside e. Largest one day price drop After consolidation since January 2022, NSE:GUFICBIO gave a break out of 12th April, went down below the support level and has given a bounce back today. Buy with a stop at ₹236. Other fundamentals: 1. The company has delivered good profit growth of 43.44% CAGR over last 5 years. 2. The company has a good return on equity (ROE) track record: 3 Years ROE 27.89%. 3. The company's median sales growth is 22.02% of last 10 year. 4. TTM sales growth of 71% and TTM profit growth of 160%. 5. Borrowings came down from ₹126cr on March 2020 to ₹35cr on September 2021. 6. Promoter holding increased from 65% in June 2021 to 75% in September 2021. 7. CRISIL Ratings has revised its outlook on the long-term bank facilities of Gufic Biosciences Limited (GBL) to 'Positive' from 'Stable', while reaffirming the rating at 'CRISIL BBB+'. and has assigned its 'CRISIL A2' rating to the short-term bank facility. The outlook revision reflects improvement in GBL’s business risk profile in fiscal 2022, marked by expected revenue of Rs. 750 crore, increase from Rs 488 crores in fiscal 2021, driven by capacity expansion and higher revenue from critical drugs. Operating profitability improved in fiscal 2021 to 17.6% and expected to sustain in fiscal 2022. With further capacity expansion in FY2023, revenue is expected to grow in future years. Hence, sustenance of operating margin and revenue growth will remain key rating sensitivity factors. Financial profile and liquidity continue to be strong. 8. GBL obtained various certifications and approvals for its manufacturing facilities and diversified its product portfolio through continuous research and development. The top 10 products contributed to 34% of revenue till the third quarter of fiscal 2022. Revenue grew to an estimated Rs 750 crore in fiscal 2022 from Rs 300 crore in fiscal 2018. 9. Financial risk should remain strong despite the huge, debt-funded capex to be undertaken in fiscal 2023. Networth was Rs 173 crore as on March 31, 2021 and is estimated at Rs 250 crore on March 31, 2022. Its controlled reliance on external debt has led to comfortable gearing and total outside liabilities to adjusted networth (TOLANW) ratios, which are estimated to be 0.14-0.15 times and 0.8-0.9 times, respectively in fiscal 2022. Debt protection metrics are robust, with interest coverage and net cash accrual to adjusted debt ratios estimated at 25 times and 2.5 times, respectively, for fiscal 2022.
NSE:GUFICBIOLong
by akashbothra